Latest / The Well-Built Life / Bone Marrow’s Role in Alzheimer's: New Insights
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:19Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:24Speaker 1: and let's dive in. All right, folks, let's dive right
- 0:26Speaker 1: into today's episode. We have heard lots about Alzheimer's disease
- 0:30Speaker 1: for decades now, focusing mainly on the brain with treatments
- 0:34Speaker 1: targeting beta amyloid and tau protein buildup. But Therese, a
- 0:38Speaker 1: fascinating paradigm shifting study that might just change our understanding
- 0:43Speaker 1: of the disease specifically from the University of California, San Francisco.
- 0:48Speaker 1: What do you think, Thomas? Is it time to turn
- 0:51Speaker 1: our attention away from the brain a bit?
- 0:52Speaker 2: Absolutely. It's intriguing, right? Traditionally, Alzheimer's has been seen as
- 0:57Speaker 2: a neurological battle, with the brain taking most of the spotlight.
- 1:01Speaker 2: But now, researchers at UCSF are saying that the bone
- 1:05Speaker 2: marrow might be the unsung hero. Or rather, the unsung
- 1:09Speaker 2: villain of the story. Let's break it down. What's the
- 1:12Speaker 2: core of this new research?
- 1:14Speaker 1: Great question. So, the key here is the bone marrow's
- 1:17Speaker 1: role in producing specialized immune cells, specifically the monocytes. These
- 1:22Speaker 1: cells are supposed to help clear out harmful proteins like beta, amyloid,
- 1:27Speaker 1: and tau. But in Alzheimer's patients, the bone marrow seems
- 1:30Speaker 1: to produce fewer and less effective monocytes, which means the
- 1:35Speaker 1: brain doesn't get the support it needs to fight the disease.
- 1:38Speaker 2: Exactly. And it's not just a surface-level issue. It goes
- 1:41Speaker 2: much deeper. For instance, in mouse models, the bone marrow
- 1:45Speaker 2: stem cells mature prematurely, leading to a decline in the
- 1:49Speaker 2: production of these crucial monocytes. humans exhibit a similar pattern,
- 1:53Speaker 2: showing that this isn't just an anomaly in mice. How
- 1:56Speaker 2: does the body's response to the disease change when this
- 1:59Speaker 2: critical cell production is compromised?
- 2:02Speaker 1: Right. It's fascinating. These findings challenge the traditional view that
- 2:07Speaker 1: Alzheimer's is purely a brain problem. It suggests that the
- 2:11Speaker 1: failure to clear these toxic proteins could be a systemic issue.
- 2:15Speaker 1: affecting the bone marrow and its ability to supply the
- 2:18Speaker 1: brain with the right immune cells.
- 2:19Speaker 2: That's wild when you look at the raw numbers. For instance,
- 2:23Speaker 2: in the study, when they used targeted therapy to restore
- 2:26Speaker 2: bone marrow function in mice, it resulted in ameliorated disease
- 2:30Speaker 2: pathology and an increase in monocyte-derived macrophages in the brain.
- 2:35Speaker 2: This shows that addressing bone marrow function might be a
- 2:38Speaker 2: key to improving brain health and potentially a new avenue
- 2:41Speaker 2: for treatment.
- 2:42Speaker 1: Exactly. And that's what I was going to say. So,
- 2:46Speaker 1: moving forward, this opens the door to possibly new treatment
- 2:49Speaker 1: strategies focused on the bone marrow. It's like looking at
- 2:53Speaker 1: an old problem with a new lens. We have been
- 2:56Speaker 1: focusing so much on the brain that we might have
- 2:58Speaker 1: overlooked these systemic factors. How do you think this will
- 3:02Speaker 1: impact the field of Alzheimer's research and treatment?
- 3:05Speaker 2: It's a big shift for sure. On the one hand,
- 3:08Speaker 2: it optimistically suggests that there might be new, potentially more
- 3:11Speaker 2: effective therapies. On the other, there are still unanswered questions.
- 3:16Speaker 2: Can we translate these findings from mice to human patients?
- 3:19Speaker 2: And how do we go about preserving or enhancing bone
- 3:22Speaker 2: marrow function in Alzheimer's patients to improve their immune response?
- 3:26Speaker 1: Well said. It's all about the balance between optimism and caution.
- 3:31Speaker 1: This study is just the beginning. The real work lies
- 3:34Speaker 1: in validating these findings and developing targeted therapies that can
- 3:39Speaker 1: help these patients. It's a new chapter in Alzheimer's research.
- 3:43Speaker 1: and we are excited to see where it leads. Thomas,
- 3:46Speaker 1: you mentioned earlier the mice models showed interesting parallels to
- 3:49Speaker 1: human patients. Can you dig a bit deeper into that?
- 3:53Speaker 1: What exactly did they find in the mice that mirrored
- 3:55Speaker 1: what's happening in patients?
- 3:57Speaker 2: Absolutely. The research really highlights the consistency between the mice
- 4:02Speaker 2: models and human patients. In the mice, we saw premature
- 4:05Speaker 2: maturation of bone marrow stem cells. which led to a
- 4:08Speaker 2: reduced production of monocytes. These monocytes are crucial because they
- 4:13Speaker 2: are the immune system's frontline soldiers responsible for fighting off
- 4:17Speaker 2: harmful proteins like amyloid beta that accumulate in the brain. Essentially,
- 4:23Speaker 2: the bone marrow is producing less effective soldiers, and that's
- 4:26Speaker 2: not just affecting the brain, but also the whole body's
- 4:29Speaker 2: response to the disease.
- 4:30Speaker 1: That's a really telling point. So if I understand correctly,
- 4:34Speaker 1: the mice models not only show impaired monocyte development, but
- 4:38Speaker 1: also indicate that these cells end up being less effective
- 4:41Speaker 1: when they do make it to the brain. This suggests
- 4:44Speaker 1: that the bone marrow isn't just producing the wrong types
- 4:46Speaker 1: of cells, but it's also producing fewer of them, right?
- 4:50Speaker 2: Exactly. And this is the crux of the matter. The
- 4:53Speaker 2: mice models reveal that not only are there fewer monocytes
- 4:56Speaker 2: in circulation, but those that do exist are less capable
- 5:00Speaker 2: of performing their functions. In the human patients, we see
- 5:03Speaker 2: a similar phenotype. The circulating monocytes in Alzheimer's, Patients exhibit
- 5:08Speaker 2: the same characteristics as those in the diseased mice. This
- 5:13Speaker 2: is a strong indicator that the findings might have broader applicability,
- 5:16Speaker 2: potentially even being relevant to other neurodegenerative diseases.
- 5:20Speaker 1: Interesting. What does this tell us about the future direction
- 5:24Speaker 1: of Alzheimer's research? Are we looking at a shift away
- 5:28Speaker 1: from brain-centric treatments towards more systemic approaches?
- 5:31Speaker 2: Absolutely. To raise a growing consensus that the traditional brain-centric
- 5:36Speaker 2: approach might be missing a crucial piece, the study's lead
- 5:39Speaker 2: scientists are optimistic about the potential for systemic therapies that
- 5:43Speaker 2: could target the bone marrow directly. This could involve treatments
- 5:47Speaker 2: that enhance the self-renewal of bone marrow stem cells, potentially
- 5:51Speaker 2: improving the overall immune response in the brain. It's a
- 5:55Speaker 2: paradigm shift, and it's exciting to see where this research
- 5:59Speaker 2: takes us.
- 5:59Speaker 1: Right. And what about the challenges that come with translating
- 6:03Speaker 1: these findings from mice to humans? Are there any specific
- 6:07Speaker 1: concerns or hurdles that need to be addressed?
- 6:10Speaker 2: There are definitely challenges. For now, the findings have been
- 6:14Speaker 2: validated in mice. And while the phenotype in humans is similar,
- 6:18Speaker 2: the actual mechanisms may differ. That's why ongoing research is
- 6:22Speaker 2: critical to validate these findings in a clinical setting. Clinicians
- 6:26Speaker 2: and researchers must work more closely to develop therapies that
- 6:30Speaker 2: can effectively restore bone marrow function in humans without causing
- 6:34Speaker 2: other complications. It's a complex process, but the potential rewards
- 6:39Speaker 2: are huge.
- 6:40Speaker 1: Indeed. So, as we move forward, what's the takeaway for
- 6:45Speaker 1: someone tuning in today? How can this research impact their
- 6:49Speaker 1: understanding of both Alzheimer's and potential new treatments.
- 6:53Speaker 2: The key takeaway is that Alzheimer's might not just be
- 6:56Speaker 2: a brain disease. The bone marrow plays a significant role,
- 7:00Speaker 2: and addressing bone marrow dysfunction could lead to new therapeutic avenues.
- 7:04Speaker 2: It's important to keep an open mind and embrace this
- 7:07Speaker 2: new systemic perspective. For now, these findings suggest that future
- 7:11Speaker 2: treatments might need to target both the brain and the
- 7:14Speaker 2: immune system more holistically.
- 7:16Speaker 1: Agreed. And who knows? It might just change the way
- 7:19Speaker 1: we think about chronic neurological conditions. Thanks for diving into this, Thomas.
- 7:26Speaker 1: This really helps us frame the next steps in our
- 7:29Speaker 1: research and treatment strategies.
- 7:31Speaker 2: Absolutely, Rachel. This collaboration between the brain and the immune
- 7:35Speaker 2: system is opening up new avenues we couldn't even imagine before.
- 7:39Speaker 2: It's an exciting time.
- 7:41Speaker 1: So, Thomas, this paradigm shift in understanding Alzheimer's could have
- 7:46Speaker 1: major implications. How do you see scientists responding to this?
- 7:51Speaker 1: Are they shifting their focus now?
- 7:53Speaker 2: Absolutely, Rachel. The paradigm shift is already pushing scientists in
- 7:58Speaker 2: a new direction. They are starting to see the brain
- 8:01Speaker 2: as part of a larger system rather than an isolated battlefield.
- 8:06Speaker 2: For instance, researchers are now focusing on bone marrow stem
- 8:09Speaker 2: cells and their influence on monocyte development. This is a
- 8:13Speaker 2: game changer because it means we could be looking at
- 8:16Speaker 2: new targets for therapy that weren't on the radar before.
- 8:19Speaker 1: Right. And that's the crucial nuance here. It's not just
- 8:23Speaker 1: about the brain anymore. What about the patients and caregivers?
- 8:28Speaker 1: How are they faring in this new landscape?
- 8:30Speaker 2: Great question. Patients and caregivers are hopeful because of the
- 8:34Speaker 2: potential for new, more comprehensive treatments. But the path from
- 8:38Speaker 2: here to clinical applications is long. We need more research
- 8:42Speaker 2: to show that the findings in mice actually translate to humans.
- 8:46Speaker 2: In the meantime, they are cautiously optimistic, hanging on to
- 8:50Speaker 2: every piece of promising news, hoping for breakthroughs.
- 8:54Speaker 1: Exactly. Which brings up an interesting contradiction. The traditional treatments
- 8:59Speaker 1: focused on beta amyloid and tau protein buildup haven't shown
- 9:03Speaker 1: the curative results we'd hoped. Now, this new research suggests
- 9:08Speaker 1: we might be overlooking an essential component of the disease.
- 9:11Speaker 1: How do we reconcile these conflicting ideas?
- 9:15Speaker 2: It's a valid point, Rachel. The historical focus on beta
- 9:18Speaker 2: amyloid and tau protein was a crucial start, but it
- 9:22Speaker 2: painted an incomplete picture of the disease. This new research
- 9:26Speaker 2: adds layers, showing us that the brain and immune system
- 9:29Speaker 2: are intertwined. This means we need to approach Alzheimer's from
- 9:33Speaker 2: a whole body perspective, not just treating the brain. It's
- 9:37Speaker 2: like looking at a plant. You can't just water the
- 9:40Speaker 2: leaves if the roots are dry.
- 9:42Speaker 1: Wait, but how does that actually play out in practice?
- 9:46Speaker 1: Are we talking about bone marrow transplants or something more subtle?
- 9:50Speaker 2: That's a great question, and it's still early days. For now,
- 9:54Speaker 2: it's about developing therapies that can enhance the bone marrow's
- 9:58Speaker 2: ability to produce healthy monocytes. Think of it like a
- 10:01Speaker 2: reboot for the immune system. If we can get the
- 10:04Speaker 2: right stem cells to mature properly and then migrate to
- 10:07Speaker 2: the brain, we might see significant improvements in how the
- 10:10Speaker 2: brain manages the plaque buildup. It's not so much a
- 10:14Speaker 2: transplant as it is a targeted therapy aimed at fixing
- 10:17Speaker 2: the underlying issue.
- 10:18Speaker 1: That's wild when you look at the raw numbers. The
- 10:21Speaker 1: research so far shows promising results in mice, but translating
- 10:26Speaker 1: that to human patients is another ballgame entirely, right?
- 10:31Speaker 2: Exactly. The numbers are exciting, but the real challenge is
- 10:34Speaker 2: in the translational gap. We need to carefully design human
- 10:38Speaker 2: studies to see if the same effects are seen. its
- 10:41Speaker 2: early days, and to raise a lot of room for skepticism.
- 10:44Speaker 2: But it's also a thrilling opportunity to reshape the approach
- 10:47Speaker 2: to Alzheimer's, moving from a one-size-fits-all to a more personalized,
- 10:52Speaker 2: systemic treatment.
- 10:53Speaker 1: Thanks, Thomas. This has really broadened our perspective. It's clear
- 10:58Speaker 1: that the roles of scientists, patients, caregivers, and medical institutions
- 11:03Speaker 1: are evolving in this new landscape. Looking forward, What do
- 11:08Speaker 1: you think will be the biggest impact of these findings?
- 11:11Speaker 2: I believe it will be the way we think about
- 11:13Speaker 2: and research Alzheimer's in the future. We are moving towards
- 11:17Speaker 2: a more integrated, holistic approach. This could not only change
- 11:21Speaker 2: treatment strategies, but also how we screen and diagnose the disease.
- 11:26Speaker 2: It's a whole new frontier, and I think we are
- 11:29Speaker 2: just scratching the surface.
- 11:30Speaker 1: So, Thomas, can we dive into the divide here? On
- 11:34Speaker 1: the one hand, to raise this optimism that this new
- 11:37Speaker 1: understanding of the bone marrow's role might lead to more
- 11:40Speaker 1: effective therapeutic targets. But on the other, there are concerns
- 11:45Speaker 1: about how well these mouse models translate to human patients,
- 11:49Speaker 1: and the long road ahead.
- 11:50Speaker 2: Exactly, Rachel. The optimist view is that by addressing the
- 11:54Speaker 2: systemic issues, we might find ways to bolster the immune
- 11:57Speaker 2: system's ability to clear out harmful plaques. Yet, the pessimist
- 12:02Speaker 2: might argue that mouse models don't always mirror human biology,
- 12:06Speaker 2: and we are still years away from practical treatments.
- 12:09Speaker 1: Right. Let's unpack the optimist perspective. First, how does this
- 12:14Speaker 1: new understanding open doors for potential therapies?
- 12:17Speaker 2: Well, it suggests that by targeting bone marrow stem cells,
- 12:21Speaker 2: we can potentially increase the production of monocytes that specifically
- 12:25Speaker 2: target the brain. This is a shift from the traditional
- 12:28Speaker 2: focus on cerebral amyloid clearance to a systemic approach. It
- 12:32Speaker 2: could lead to therapies that enhance the body's natural defenses
- 12:35Speaker 2: against the disease.
- 12:36Speaker 1: That's a compelling idea. And what about the risk of
- 12:40Speaker 1: this being overly optimistic, given the limitations of mouse models?
- 12:44Speaker 2: Absolutely. Therese always the concern that while the mechanisms might
- 12:49Speaker 2: hold a lot of promise, they may not translate. Mouse
- 12:52Speaker 2: models are useful, but they are far from perfect. We
- 12:56Speaker 2: need more human studies to validate these findings and see
- 12:59Speaker 2: if the same outcomes can be achieved in clinical settings.
- 13:02Speaker 1: But let's also consider the broader impact if this new
- 13:05Speaker 1: research is successful. How might it change how we view
- 13:09Speaker 1: neurodegenerative diseases in general?
- 13:11Speaker 2: Broadly, it could lead to a reclassification of these diseases
- 13:15Speaker 2: as systemic rather than just cerebral. This might mean a
- 13:18Speaker 2: shift in the way we approach diagnosis and treatment, potentially
- 13:22Speaker 2: integrating more holistic approaches that address the body as a whole.
- 13:25Speaker 2: not just the brain.
- 13:27Speaker 1: That's profound. And as we look at potential challenges, what
- 13:32Speaker 1: are the critical questions we need to address next?
- 13:34Speaker 2: We need to focus on the translatability of these findings
- 13:38Speaker 2: from mouse to human. Are the changes in bone marrow
- 13:41Speaker 2: stem cell function in mice mirrored in patients? And even
- 13:45Speaker 2: if the mechanisms are the same, how do we develop
- 13:48Speaker 2: therapies that can effectively target these changes in a human body?
- 13:52Speaker 1: And finally, Thomas, what do you think will be the
- 13:56Speaker 1: biggest immediate impact of this paradigm shift?
- 13:59Speaker 2: I think the biggest impact will be on the prioritization
- 14:02Speaker 2: of multifaceted research approaches. We might see more funding and
- 14:06Speaker 2: resources directed towards understanding the systemic aspects of these diseases,
- 14:11Speaker 2: rather than just focusing on brain-centric solutions. This could lead
- 14:16Speaker 2: to a more integrated approach to health and disease management.
- 14:19Speaker 1: So, Thomas, as we wrap up today's discussion, it's clear
- 14:23Speaker 1: that the paradigm shift in our understanding of Alzheimer's is significant.
- 14:28Speaker 1: But what are the current challenges we face in translating
- 14:31Speaker 1: these findings into actual treatments?
- 14:34Speaker 2: Exactly, Rachel. One of the biggest challenges is the transition
- 14:38Speaker 2: from mouse models to human patients. The findings in mice
- 14:42Speaker 2: show great promise, but clinical trials with human subjects will
- 14:45Speaker 2: be crucial to validate these results. We need to determine
- 14:49Speaker 2: if the bone marrow's changes in human patients are as
- 14:52Speaker 2: direct and robust as in the mice. True.
- 14:55Speaker 1: And how do we address the potential translational challenges? Are
- 14:59Speaker 1: there specific areas of focus among the researchers and medical institutions?
- 15:04Speaker 2: Absolutely. The research community and medical institutions are certainly paying attention.
- 15:10Speaker 2: They are focusing on identifying the specific mechanisms behind the
- 15:14Speaker 2: bone marrow's failure to produce healthy monocytes. and exploring ways
- 15:18Speaker 2: to restore this function. Therese also a push to understand
- 15:22Speaker 2: the role of systemic inflammation and how it links to
- 15:25Speaker 2: brain health.
- 15:26Speaker 1: Right. And Thomas, can you speak a bit more to
- 15:29Speaker 1: the economic and social implications of this research? How might
- 15:34Speaker 1: it influence funding and resource allocation in the health sector?
- 15:38Speaker 2: Certainly. If this research leads to new therapeutic targets, it
- 15:42Speaker 2: could realign funding towards a more systemic approach to Alzheimer's.
- 15:47Speaker 2: more resources might be directed towards the development of stem
- 15:50Speaker 2: cell therapies that directly address the bone marrow's role. This
- 15:53Speaker 2: shift could also have broader implications potentially reshaping how we
- 15:57Speaker 2: fund and conduct research across the board.
- 15:59Speaker 1: That's an interesting point. On a practical level, what actionable
- 16:03Speaker 1: steps can we take based on this research?
- 16:06Speaker 2: Well, one key step is supporting ongoing clinical trials that
- 16:10Speaker 2: test therapies aimed at enhancing bone marrow function. Additionally, Promoting
- 16:16Speaker 2: interdisciplinary collaboration between immunologists, neurologists, and hematologists could accelerate breakthroughs. Lastly,
- 16:24Speaker 2: advocating for increased research funding in this area can help
- 16:28Speaker 2: unlock the potential of these new therapeutic targets. Agreed.
- 16:32Speaker 1: So looking to the future, what's the big picture here?
- 16:35Speaker 1: How might this research fundamentally change our approach to Alzheimer's treatment?
- 16:39Speaker 2: It's all about adopting a more holistic view. The research
- 16:43Speaker 2: reminds us that Alzheimer's is not just a brain disease,
- 16:46Speaker 2: it's part of a broader physiological system. By focusing on
- 16:49Speaker 2: the bone marrow, we open up new avenues for both
- 16:52Speaker 2: diagnosis and treatment. This could lead to a more effective
- 16:56Speaker 2: and integrated approach, potentially reducing not only the symptoms, but
- 17:00Speaker 2: also the progression of the disease.
- 17:02Speaker 1: That's very encouraging. Thanks for the insightful discussion, Thomas. This
- 17:08Speaker 1: has been a really enlightening conversation.
- 17:10Speaker 2: The pleasure's mine, Rachel. It's great to explore the complexities
- 17:15Speaker 2: of Alzheimer's and the exciting new avenues this research opens up.
- 17:19Speaker 1: That brings us to the end of today's episode. Thank
- 17:22Speaker 1: you so much for spending part of your day with me.
- 17:24Speaker 1: If you found this episode's tips helpful and want to
- 17:27Speaker 1: make sure you don't miss the next conversation, please take
- 17:30Speaker 1: a quick second to hit that subscribe or follow button
- 17:33Speaker 1: on whatever platform you are listening on. It's a completely
- 17:36Speaker 1: free way to support the show and helps more people
- 17:39Speaker 1: find us. This podcast is independently produced, so if you
- 17:43Speaker 1: are ever in a position where you would like to
- 17:45Speaker 1: help keep it running, we do accept small donations. You
- 17:49Speaker 1: can find a link right in the episode description below
- 17:51Speaker 1: to buy us a coffee or contribute what you can.
- 17:54Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 17:59Speaker 1: and we will talk again soon.